NHGRI’s effort to ensure that this new trove of sequence data is translated into powerful tools and thoughtful strategies to advance biological knowledge and improve human health. Dr. Collins is also known for his consistent emphasis on the importance of ethical and legal issues in genetics. In addition to his achievements as the NHGRI director, Dr. Collins’s laboratory has discovered a number of important genes, including those responsible for cystic fibrosis, neurofibromatosis, Huntington’s disease, and most recently, the gene that causes Hutchinson-Gilford progeria syndrome, a dramatic form of premature aging. Dr. Collins received a B.S. from the University of Virginia, a Ph.D. in physical chemistry from Yale University, and an M.D. from the University of North Carolina. He is a member of the Institute of Medicine and the National Academy of Sciences.
David R. Cox, M.D., Ph.D., is chief scientific officer of Perelegen Sciences, Inc. Dr. Cox is internationally recognized for his research on the molecular basis of human genetic disease. After receiving B.A. and M.S. degrees from Brown University in Rhode Island, Dr. Cox obtained M.D. and Ph.D. degrees from the University of Washington, Seattle. He then completed his pediatric residency at the Yale-New Haven Hospital in New Haven, Connecticut, and was a fellow in both genetics and pediatrics at the University of California, San Francisco. From 1980 to 1993, Dr. Cox held faculty positions in the Departments of Pediatrics, Biochemistry, and Psychiatry at the University of California, San Francisco. In 1993, he accepted a position as a professor of genetics and pediatrics at the Stanford University School of Medicine as well as the position of codirector of the Stanford Genome Center. In October 2000, Dr. Cox left his position at Stanford University to become the chief scientific officer of Perelegen Sciences, Inc. Dr. Cox is certified by both the American Board of Pediatrics and the American Board of Medical Genetics. He has served on several international and national councils and commissions, including the Council of the Human Genome Organization and the National Bioethics Advisory Commission. He currently serves as a member of the Health Sciences Policy Board of the Institute of Medicine. Dr. Cox’s honors include election to the Institute of Medicine of the National Academy of Sciences.
Patricia Danzon, Ph.D., is the Celia Moh Professor at the Wharton School of Management, University of Pennsylvania, where she is also professor and chair of the Health Care Systems Department and professor of insurance and risk management. Professor Danzon received a B.A. from Oxford University, Oxford, England, and a Ph.D. in economics from the University of Chicago. Professor Danzon is an internationally recognized expert in the fields of health care, pharmaceuticals, insurance, and liability